Inverna Therapeutics BioFIT 2026 Marseille

Press release

Odense, Denmark – July 24, 2026 – Marseille, France will be hosting the 15th edition of BioFIT – The leading European partnering event for early-stage deals and investment rounds in the Life Sciences field. And Inverna is delighted to be featuring its CEO Poul Sørensen as one of the speakers for the conference in the session titled “Fewer seed rounds and alternative financing strategies: They chose to collaborate with patient associations”.

The speakers will discuss how the current context of early-stage capital shortage has an impact on all stakeholders in life sciences. Alternative financing strategies are not only a nice way to move forward for innovation but for some it has become necessary to survive and bring their asset to patients in need. Among these strategies, some chose to collaborate with patient associations. Through their case studies, the panel of speakers will elaborate on the role these alternative financing players took in the deal and how it compares to other types of partnerships, and the outcomes of the collaborations.

“BioFIT is a leading event for technology transfer, academia-industry collaborations, early-stage innovation deals and pre-seed, seed and Series A investment in the field of Life Sciences, and hence, the perfect occasion for Inverna to share our experiences and present our portfolio and scientific progress in pursuit of new opportunities.”

said Poul Sørensen, CEO of Inverna Therapeutics.
Inverna’s CEO Poul Sørensen welcomes meeting requests

About Inverna Therapeutics

Inverna Therapeutics is a Danish biotech company, founded in 2024 emerging from Southern Danish University in Odense, nurtured by Argobio Studio, a launch platform for Europe’s best medicinal science. With our proprietary drug discovery platform, we’re dedicated to developing transformative RNA therapeutics based on precision RNA splicing modulation. Our unique technology allows us to design, test, and develop highly specific activators of pseudo-exons in disease-relevant target RNA. Today, we are pursuing breakthroughs in neurological disorders such as Parkinson’s disease, somatic repeat expansion diseases, and Huntington’s disease, knowing that the approach can extend to other organ systems and diseases.

Contact :